http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Serum Levels of Brain-Derived Neurotrophic Factor at 4 Weeks and Response to Treatment with SSRIs
Reiji Yoshimura,Taro Kishi,Hikaru Hori,Asuka Katsuki,Atsuko Sugita-Ikenouchi,Wakako Umene-Nakano,Kiyokazu Atake,Nakao Iwata,Jun Nakamura 대한신경정신의학회 2014 PSYCHIATRY INVESTIGATION Vol.11 No.1
Objective It is important to predict a response to an antidepressant in early time after starting the antidepressant. We previously reportedthat serum brain-derived neurotrophic factor (BDNF) levels in responders to treatment with antidepressants were increased,whereas, those in nonresponders were not. Therefore, we hypothesized that the changes in serum levels of BDNF from baseline (T0) to4 weeks (T4) after treatment with selective serotonin reuptake inhibitors (SSRIs) predict the response to the treatment at 8 weeks (T8) indepressed patients. To confirm the hypothesis, we measured serum BDNF at T0, T4, and T8 during the treatment with SSRIs (paroxetine,sertraline, and fluvoxamine). Methods One hundred fifty patients (M/F; 51/99, age; 50.4±15.1 years) met major depressive disorder (MDD) using by DSM-IV-TRenrolled in the present study. We measured serum BDNF concentrations at T0, T4, and T8 in patients with MDD treated with SSRIs. Results The changes in serum BDNF, age, sex, dose of SSRIs, and HAMD-17 score did not predict the response to SSRIs at T8. Conclusion These results suggest that the changes in serum BDNF levels from T0 to T4 could not predict the subsequent responses toSSRIs at T8.
Reiji Yoshimura,Taro Kish,Hikaru Hori,Atsuko Ikenouchi-Sugita,Wakako Umene-Nakano,Asuka Katsuki,Kenji Hayashi,Nakao Iwata,Jun Nakamura 대한정신약물학회 2012 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.10 No.1
Objective: This study examined the association between the brain-derived neurotrophic factor (BDNF) (Val66Met) polymorphism and the response to the addition of an atypical antipsychotic drug to a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) in treatment-refractory depression. Methods: The study enrolled 64 patients meeting the Diagnostic and Statistical Manual of Mental Disorders-IV criteria for major depressive disorder who were treated with at least two courses of a single antidepressant, but who had Hamilton Depression Rating Scale (HAMD-17) scores ≥15 points that were reduced less than 50% over at least a 4-week treatment period. There were 24 males and 40 females (age range 27-68 years; mean±SD, 48±13 years). The patients' clinical improvement was evaluated using the HAMD-17. Patients with at least a 50% decrease in the HAMD-17 score were defined as responders. Serum BDNF levels were assayed using enzyme-linked immunosorbent assays and the presence of the BDNF (Val66Met) polymorphism was determined using the TaqMan genotyping assay. Results: No correlation was found between the BDNF (Val66Met) polymorphism and a positive response to adding an atypical antipsychotic drug. No differences were observed in the changes in the serum BDNF levels and HAMD-17 scores between Val66Val and Met-carriers. In addition, in patients who experienced remission, the atypical antipsychotic drug was discontinued after at least 3 months of treatment and the patients were then followed for 1 year; 14 of 27 patients (52%) relapsed within 1 year. Conclusion: These results suggest that the BDNF (Val66Met) polymorphism is not associated with the response to the augmentation of a SSRI or SNRI with an atypical antipsychotic drug, and that the combination of an atypical antipsychotic drug and a SSRI or SNRI should be continued for 3 months or more in refractory depressed patients in the Japanese population.
Development and Performance Test of the Analysis Software for the CRIB Active Target
이필수,이춘식,문준영,채경육,차수미,Hidetoshi Yamaguchi,Taro Nakao,David M. Kahl,Shigeru Kubono,Silvio Cherubini,Seiya Hayakawa,Cosimo Signorini 한국물리학회 2015 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.66 No.3
Software for genuinely event-by-event analysis and event reconstruction of data obtained by usingan active target has been developed in the graphical user interface under the CERN ROOT framework. The primary motivation for developing the software was to provide physicists who performexperiments using an active target a more user-friendly environment for the purpose of investigatingthe performance of detection systems and obtaining ideas about physics from a large amount ofexperimental data. To test the performance of the software, we analyzed experimental data froma 16N radioactive ion beam experiment for α-decay measurements. As a result of the analysis, weobserved the Bragg curve and measured the range of the 16N RI beam in the detector. Data werecalibrated against the calculation after comparing the Bragg curve to the one obtained from anenergy loss calculation in P-10 gas. We present a detailed description of the analysis software andits test results.